From Editing Genes to Rewriting Them
For more than a decade, CRISPR-Cas9 has dominated the conversation around genome engineering. By enabling researchers to cut DNA with remarkable precision, CRISPR transformed genetic medicine from a scientific ambition into a clinical reality. Today, approved therapies and late-stage clinical programs are proving that genome editing can deliver meaningful benefit for patients.
But the field is already looking beyond cutting and repairing DNA.
A new generation of technologies, collectively known as gene writing, is emerging with the promise of making larger, more sophisticated genetic changes than ever before. Rather than correcting a single mutation, gene writing aims to insert entire functional DNA sequences, replace defective exons, and potentially address diseases that remain beyond the reach of traditional editing approaches.
It represents one of the most significant shifts in genome engineering since the emergence of CRISPR itself.
Why Now?
The timing could not be more important. The FDA's proposed Plausible Mechanism Pathway has created a potential new route for genome editing therapies targeting ultra-rare diseases, reducing some of the clinical challenges that have historically slowed development. At the same time, investors continue to place substantial bets on next-generation genome engineering platforms despite wider market caution.
Perhaps the clearest indicator of momentum came from Regeneron's investment in Tessera Therapeutics, whose Gene Writing™ technology aims to move beyond conventional gene editing and enable precise DNA insertion at scale.
As developers seek to expand into larger genetic disorders and more complex disease biology, the limitations of first-generation editing tools are becoming increasingly apparent. Gene writing offers a pathway to overcome them.
The Technologies Driving the Transition
The movement toward gene writing is being fuelled by rapid innovation across multiple modalities, including:
Prime Editing
Integrase-Based Systems
CRISPR-Associated Transposases (CASTs)
Site-Specific Recombination Technologies
Programable DNA Insertion Platforms
Novel Delivery Approaches Capable of Transporting Larger Genetic Payloads
Many of these technologies are seeking to solve a common problem: how to make larger, more precise genomic changes while maintaining safety and efficiency.
The Challenge Remains Translation
Despite the excitement surrounding next-generation technologies, the industry faces a familiar challenge: translation.
The scientific innovation is moving faster than clinical validation. Developers must still overcome delivery limitations, manufacturing complexity, off-target risks, durability questions, and evolving regulatory expectations.
For many companies, the question is no longer whether the technology works in the laboratory. The question is how quickly these advanced platforms can generate the safety and efficacy data needed to reach patients.
This is why discussions are increasingly shifting from discovery toward product development, translational science, regulatory strategy, and clinical execution.
Why the 7th Genome Editing Therapeutics Summit Matters
The 7th Genome Editing Therapeutics Summit arrives at a pivotal moment for the field.
As the industry's only therapeutic-focused genome editing meeting dedicated to the application of breakthrough technologies, this summit brings together the organizations shaping the future of genetic medicine. Attendees will hear from leaders across clinical-stage biotechs, emerging innovators, large pharma, and academic pioneers exploring next-generation gene engineering.
With speakers and target contributors including Prime Medicine, Beam Therapeutics, Intellia Therapeutics, Metagenomi, Eli Lilly, AbbVie, Scribe Therapeutics and more, the discussion will focus not simply on what is possible, but how these technologies can be translated into real therapies.
Gene editing showed the world that DNA could be changed. Gene writing could show the world that DNA can be rewritten. The companies that successfully bridge that gap may define the next decade of genetic medicine.
Explore the Agenda
See exactly which delivery, manufacturing and regulatory sessions are relevant to your genome editing program.
Partner With Us
Put your solutions in front of the genome editing decision-makers actively looking for them.
Join Genome Editing Experts
Connect with the R&D, clinical and regulatory leaders driving genome editing therapeutics forward.